Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of four randomized controlled trial(s). ^[1-4]
• In adults with idiopathic and diabetic gastroparesis (n = 201), tradipitant did not reduce average nausea severity at week 12 in the ITT population (P = 0.741); significant improvement in nausea severity was reported in subjects with high blood levels of tradipitant.
• In adults with a history of motion sickness during boat trips under variable sea conditions (n = 365), vomiting occurred in 18.3% with 170 mg tradipitant and 19.5% with 85 mg tradipitant versus 44.3% with placebo (p < 0.0001 for both dosages); severe nausea and vomiting occurred in 18.03% with tradipitant versus 37.70% with placebo (p < 0.0001).
• In healthy volunteers (n = 24), tradipitant 85 mg b.i.d. for 9 days did not significantly affect gastric emptying, gastric volumes, satiation, or postprandial symptoms compared with placebo.
• In adults with idiopathic and diabetic gastroparesis (n = 201), healthy participants without antiemetic treatment (n = 63), healthy volunteers assessed for gastric motor functions (n = 24), and adults with a history of motion sickness (n = 365), no specific safety outcomes or adverse effects were reported or assessed; the motion sickness scale validation study focused on scale validation rather than drug safety.
• There is no population types or subgroups information available in the reviewed studies.